Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform Study of Refractory/Recurrent Acute Myeloid Leukemia
NCT06265545Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of venetoclax, lisaftoclax, ivosidenib and gilteritinib in acute myeloid leukemia (AML) (8 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complex Response Rate up to 4 years. Started Feb 2024; status: recruiting.
02
Drugs
venetoclaxlisaftoclaxivosidenibgilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06265545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06265545.